The tyrosine kinase inhibitor imatinib mesylate suppresses uric acid crystal-induced acute gouty arthritis in mice

Reber, Laurent L.; Starkl, Philipp; Balbino, Bianca; Sibilano, Riccardo; Gaudenzio, Nicolas; Rogalla, Stephan; Sensarn, Steven; Kang, Dongmin; Raghu, Harini; Sokolove, Jeremy; Robinson, William H.; Contag, Christopher H.; Tsai, Mindy; Galli, Stephen J.
October 2017
PLoS ONE;10/05/2017, Vol. 12 Issue 10, p1
Academic Journal
Gouty arthritis is caused by the deposition of monosodium urate (MSU) crystals in joints. Despite many treatment options for gout, there is a substantial need for alternative treatments for patients unresponsive to current therapies. Tyrosine kinase inhibitors have demonstrated therapeutic benefit in experimental models of antibody-dependent arthritis and in rheumatoid arthritis in humans, but to date, the potential effects of such inhibitors on gouty arthritis has not been evaluated. Here we demonstrate that treatment with the tyrosine kinase inhibitor imatinib mesylate (imatinib) can suppress inflammation induced by injection of MSU crystals into subcutaneous air pouches or into the ankle joint of wild type mice. Moreover, imatinib treatment also largely abolished the lower levels of inflammation which developed in IL-1R1-/- or KitW-sh/W-sh mice, indicating that this drug can inhibit IL-1-independent pathways, as well as mast cell-independent pathways, contributing to pathology in this model. Imatinib treatment not only prevented ankle swelling and synovial inflammation when administered before MSU crystals but also diminished these features when administrated after the injection of MSU crystals, a therapeutic protocol more closely mimicking the clinical situation in which treatment occurs after the development of an acute gout flare. Finally, we also assessed the efficiency of local intra-articular injections of imatinib-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles in this model of acute gout. Treatment with low doses of this long-acting imatinib:PLGA formulation was able to reduce ankle swelling in a therapeutic protocol. Altogether, these results raise the possibility that tyrosine kinase inhibitors might have utility in the treatment of acute gout in humans.


Related Articles

  • Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. Paniagua, Ricardo T.; Sharpe, Orr; Ho, Peggy P.; Chan, Steven M.; Chang, Anna; Higgins, John P.; Tomooka, Beren H.; Thomas, Fiona M.; Song, Jason J.; Goodman, Stuart B.; Lee, David M.; Genovese, Mark C.; Utz, Paul J.; Steinman, Lawrence; Robinson, William H. // Journal of Clinical Investigation;Oct2006, Vol. 116 Issue 10, p2633 

    Tyrosine kinases play a central role in the activation of signal transduction pathways and cellular responses that mediate the pathogenesis of rheumatoid arthritis. Imatinib mesylate (imatinib) is a tyrosine kinase inhibitor developed to treat Bcr/Abl-expressing leukemias and subsequently found...

  • Immunocompetent cell functions in Ph acute lymphoblastic leukemia patients on prolonged Imatinib maintenance treatment. Maggio, Roberta; Peragine, Nadia; Propris, Maria; Vitale, Antonella; Elia, Loredana; Calabrese, Elisabetta; Della Starza, Irene; Intoppa, Stefania; Milani, Maria; Guarini, Anna; Foà, Robin // Cancer Immunology, Immunotherapy;Apr2011, Vol. 60 Issue 4, p599 

    Imatinib mesylate (Imatinib) is a potent inhibitor of defined tyrosine kinases and is effectively used for the treatment of malignancies characterized by the constitutive activation of these tyrosine kinases, such as Philadelphia chromosome-positive (Ph) leukemias and gastrointestinal stromal...

  • The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients. Hochhaus, Andreas; Kantarjian, Hagop // Journal of Cancer Research & Clinical Oncology;Dec2013, Vol. 139 Issue 12, p1971 

    Purpose: Dasatinib is a dual Abl/Src tyrosine kinase inhibitor (TKI) designed as a prototypic short-acting BCR–ABL-targeted TKI that inhibits BCR–ABL with greater potency compared with imatinib, nilotinib, bosutinib, and ponatinib and has been shown to have potential...

  • Rational design of inhibitors that bind to inactive kinase conformations. Yi Liu; Gray, Nathanael S // Nature Chemical Biology;Jul2006, Vol. 2 Issue 7, p358 

    Many of the kinase inhibitors that have been developed such as the type I inhibitors target the ATP binding site of the kinase. Crystal structures of inhibitors like imatinib (STI571), BIRB796 and sorafenib are type II inhibitors revealed new binding mode that exploits additional binding site...

  • Imatinib mesylate-induced molecular remission of Philadelphia chromosome-positive myelodysplastic syndrome. Drummond, M W; Lush, C J; Vickers, M A; Reid, F M; Kaeda, J; Holyoake, T L // Leukemia (08876924);Feb2003, Vol. 17 Issue 2, p463 

    Leukemia (2003) 17, 463–465. doi:10.1038/sj.leu.2402814

  • Imatinib Mesylate. Davey, Monica P.; Wilkinson, Kathy // Clinical Journal of Oncology Nursing;Mar/Apr2002, Vol. 6 Issue 2, p118 

    Provides information on imatinib mesylate, a protein-tyrosine kinase inhibitor used in treatment of patients with chronic myeloid leukemia. Indications and mechanism of action; Effect on blood counts; Adverse reactions and effects; Route and dosage recommended.

  • New Drug Provides Options for Imatinib Resistance. Hogle, William P. // Clinical Journal of Oncology Nursing;Apr2005, Vol. 9 Issue 2, p145 

    Examines a phase I trial involving BMS-354825 which may indicate that an alternative treatment for patients with imatinib resistance has been found. Information on imatinib; Results of the study.

  • ENESTnd: Nilotinib induced higher response rates than imatinib for newly diagnosed CML.  // Hem/Onc Today;1/10/2010, Vol. 11 Issue 1, p16 

    This article discusses a study by Giuseppe Saglio of the University of Turin and colleagues which compared the effectiveness of nilotinib with imatinib in treating patients with chronic myeloid leukemia.

  • MOLECULAR RESPONSE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB - SINGLE CENTRE EXPERIENCE. Pavkovic, Marica; Angelkovic, Rosica; Popova-Simjanovska, Marija; Genadieva-Stavric, Sonja; Cevreska, Lidija; Stojanovic, Aleksandar // Prilozi;2015, Vol. 36 Issue 2, p179 

    Introduction of tyrosine kinase inhibitors (TKI) dramatically improves the treatment and survival of the patients with chronic myeloid leukemia (CML) in the last decade. Imatinib (IM) and other TKI induce larger percentage of complete cytogenetic response (CCyR) and major molecular response...

  • Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. Tsimberidou, Apostolia M.; Colburn, Dawn E.; Welch, Mary Alma; Cortes, Jorge E.; Verstovsek, Srdan; O'Brien, Susan M.; Albitar, Maher; Kantarjian, Hagop M.; Giles, Francis J. // Cancer Chemotherapy & Pharmacology;Sep2003, Vol. 52 Issue 3, p229 

    Purpose: The tyrosine kinase inhibitor imatinib mesylate inhibits the function of the Bcr-Abl oncoprotein associated with Philadelphia-positive chronic myelogenous leukemia (CML). Anagrelide suppresses megakaryocyte proliferation and differentiation. The objectives of this study...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics